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ABSTRACT
Objective To assess the nature and prevalence of genetic
discrimination experienced by people at risk for
Huntington’s disease who had undergone genetic testing
or remained untested.
Design Cross sectional, self reported survey.
Setting Seven genetics and movement disorders clinics
servicing rural and urban communities in Canada.
Participants 233 genetically tested and untested
asymptomatic people at risk for Huntington’s disease
(response rate 80%): 167 underwent testing (83 had the
Huntington’s disease mutation, 84 did not) and 66 chose
not to be tested.
Main outcome measures Self reported experiences of
genetic discrimination and related psychological distress
based on family history or genetic test results.
Results Discrimination was reported by 93 respondents
(39.9%). Reported experiences occurred most often in
insurance (29.2%), family (15.5%), and social (12.4%)
settings. There were few reports of discrimination in
employment (6.9%), health care (8.6%), or public sector
settings (3.9%). Although respondents who were aware
that they carried the Huntington’s disease mutation
reported the highest levels of discrimination,
participation in genetic testing was not associated with
increased levels of genetic discrimination. Family history
of Huntington’s disease, rather than the result of genetic
testing, was the main reason given for experiences of
genetic discrimination. Psychological distress was
associated with genetic discrimination (P<0.001).
Conclusions Genetic discrimination was commonly
reported by people at risk for Huntington’s disease and
was a source of psychological distress. Family history,
and not genetic testing, was the major reason for genetic
discrimination.
INTRODUCTION
Genetic medicine offers many diagnostic, treatment,
and reproductive options that can inform decision
making and relieve uncertainty. However, the power-
ful new technologies of genomics have also produced
fear of misuse of genetic information including
discrimination.
1-4 Genetic discrimination refers to the
perceived unfair treatment of individuals or their
family members based on presumed or actual genetic
differences as opposed to physical features.
5 Fear of
genetic discrimination has prevented individuals
from undergoing genetic testing
36 and participating
in genetic research.
7 This widespread concern about
genetic discrimination has heralded federal legislative
developments in the United States—namely, the
Genetic Information Nondiscrimination Act, which
prohibitstheuseofgeneticinformationinhealthinsur-
ance and employment related assessments.
8 This act
was signed into law on 21 May 2008 after near unan-
imous support from the House of Representatives and
the Senate.
Despite these significant legislative efforts to protect
individuals from the potential of genetic discrimina-
tion, the frequency and context of genetic discrimina-
tion remains largely undocumented. Reports of
genetic discrimination have been anecdotal, and alle-
gations of discrimination have usually been based on
presence of disease in contrast to genetic
predisposition.
25910 Despite calls for empirical
research to address the lack of evidence for genetic
discrimination,
11 no large scale empirical study has
investigated the nature and prevalence of genetic dis-
criminationinatestedanduntestedgeneticpopulation
thatiscurrentlyhealthybutispredictedbygenetictest-
ing to develop a genetic disease.
Huntington’s disease was the first autosomal domi-
nant genetic disease for which a predictive test was
developed that allows people at risk to know with cer-
tainty whether they have inheritedthe causative muta-
tion before they become symptomatic.
1213
Huntington’s disease is an inherited neurodegenera-
tive psychiatric disorder that usually manifests in mid-
life as a triad of psychiatric, cognitive, and movement
disturbances. Individuals affected with Huntington’s
disease experience mood and personality changes,
progressive cognitive decline, and worsening move-
ment disorder which end in death about 15-20 years
from diagnosis.
14 No treatment is available to alter
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predictivetesting,concernswereraisedaboutwhether
itwasethicaltooffertestingwithouttheavailabilityofa
treatment and whether such testing would lead to dis-
criminatorypracticesagainsthealthypeoplewhowere
found to carry the mutation.
1516
It has been over 20 years since the inception of
genetic testing for Huntington’s disease, yet little is
known about whether predictive testing results in dis-
crimination. While discrimination on the basis of
family history has been documented,
17 the question
of whether predictive testing confers a heightened
risk of discrimination has yet to be answered for any
disease. This study examined the nature and preva-
lence of genetic discrimination among asymptomatic
individuals at risk for Huntington’s disease. We
hypothesised that those who had been tested would
be at greater risk for genetic discrimination.
PARTICIPANTS AND METHODS
Study population
Weundertookacrosssectional,selfreportedsurveyof
asymptomatic people at risk for Huntington’s disease
in 2006. Seven genetics and movement disorders
clinics servicing rural and urban communities in 10
Canadian provinces participated in the study.
Approval of the relevant research ethics boards was
received, and written informed consent was received
from each participant.
We targeted asymptomatic individuals at risk for
Huntington’s disease. We classified each person in
the study according to whether they had been geneti-
callytestedforHuntington’sdiseaseand,ifso,whether
they had tested positive: from these answers we pro-
duced three categories—not tested, tested negative
for disease, and tested positive for disease. We consid-
ered only experiences of discrimination based on
genetic information and excluded those that occurred
after symptoms of Huntington’s disease had devel-
oped. The population of interest included all indivi-
duals age ≥18 years from families with Huntington’s
disease who had a Unified Huntington’s Disease
Rating Scale (UHDRS)
18 score of ≤2 and had not
beenfoundtohavesignsorsymptomsofHuntington’s
disease within the past year.
Development of the survey instrument and testing
Development of our survey instrument was informed
by a previous qualitative study of genetic discrimina-
tionamongpeopleatriskforHuntington’sdisease,
1920
and it included questions adapted (with permission)
from validated instruments.
2122 An expert reference
group from the Huntington’s Disease Medical Clinic
at the University of British Columbia validated the
questionnaireusedforourstudy.Cognitiveinterviews
were usedto test for uniformity in comprehension and
comfort with response formats, instructions, and skip
patterns.Thefinalquestionnairewasmailedto19indi-
viduals at risk for Huntington’s disease to pilot data
collection procedures (see appendix 1 on bmj.com).
The finalquestionnaireincluded 122 questions.The
sectionsfocusedon(1)geneticstatusandfamilyhistory
ofHuntington’sdisease,(2)perceptionsofgenetictest-
ing, (3) concerns and experiences of knowing about
family history, (4) concerns and experiences of know-
ing genetic test results, (5) specific incidents of unfair
treatment, (6) thoughts and experiences related to
insurance,(7)knowledgeandattitudestowardsgenetic
issues, and (8) socio-demographic information. We
report on results pertaining to sections (3) and (4)
related to experiences of genetic discrimination based
on family history and genetic test results.
Assessment of family history
The family history of respondents was assessed using
the following questions:
 In approximately what year did you first become
aware that Huntington’s disease was in your
family?
 Which of the following best describes your
experience with Huntington’s disease? (a) I have
had no prior experience with people who had
Huntington’s disease; (b) I have known people
who have had early symptoms of Huntington’s
disease; (c) I have known people who have had
severe disease or have died.
Assessment of genetic status
The genetic status of the respondents was assessed
using the following questions:
 Have you had a genetic test for Huntington’s
disease?
 Did you get a positive test result (that is, have
you inherited the Huntington’s disease gene
expansion?)
Responses to these questions formed the basis for
classifying individuals as mutation positive, mutation
negative, or not tested.
Assessment of experiences of genetic discrimination
We asked respondents whether they had ever experi-
enced discrimination in various situations because of
Questions asked about genetic discrimination in the
survey
Discrimination based on family history
We are interested in learning about experiences with
discrimination, by this we mean being unfairly prevented
fromdoingsomething,orbeingtreatedunfairly.Haveyou
ever experienced discrimination in any of the following
situations* because of yourfamily history ofHuntington’s
disease?
Discrimination based on genetic test results
We are interested in learning about experiences with
discrimination, by this we mean being unfairly prevented
fromdoingsomething,orbeingtreatedunfairly.Haveyou
ever experienced discrimination in any of the following
situations* because of your genetic test results?
*Seetable 2 for the list of situations offered.
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(seebox).Wedefineddiscriminationas“beingunfairly
prevented from doing something or being treated
unfairly,” which was the dominant interpretation pro-
vided by participants in the initial qualitative study
1920
and is consistent with the well established and vali-
dateddefinitionsofdiscrimination
2123-25 andofgenetic
discrimination specifically.
2022
The respondents were provided with a total of 23
possible contexts for discrimination (as listed in
table 2). Possible responses were “yes,”“ no,” and
“not applicable.” Respondents who answered “yes”
to any item were considered to have experienced
genetic discrimination and were counted once. In
order to identify the prevalence of genetic discrimina-
tioninmajorsettings,wecollapsedthe23itemsintosix
settings—insurance, employment, social, family, pub-
lic sector, and health care (see table 2). Settings were
not mutually exclusive, with respondents selecting all
that applied.
Assessment of psychological distress
Psychological distress was chosen a priori to be a pri-
mary outcome measure because it has been associated
withracial,sexual,andethnicdiscrimination.
26Respon-
dents who reported one or more experience(s) of
Table 1 |Demographic characteristics of 233 asymptomatic respondents at risk for Huntington’s disease. Values are numbers
(percentages) unless stated otherwise
Total (n=233)
Genetic test for mutation
Not tested (n=66)
P value of
difference* Positive (n=83) Negative (n=84)
Women 153 (65.7) 53 (63.9) 52 (61.9) 48 (72.7)
0.35
Men 80 (34.3) 30 (36.1) 32 (38.1) 18 (27.3)
Mean (SD) age (years) 45.5 (11.7) 47.0 (11.0) 46.0 (13.7) 42.9 (9.5) 0.09
Marital status (n=231):
Married or partnership 176 (76.2) 64 (79.0) 59 (70.2) 53 (80.3)
0.27
Single, separated,divorced,widowed 55 (23.8) 17 (21.0) 25 (29.8) 13 (19.7)
Education (n=226):
Some college and higher 206 (91.2) 77 (95.1) 72 (88.9) 57 (89.1)
0.30
High school or lower 20 (8.8) 4 (4.9) 9 (11.1) 7 (10.8)
Employment (n=228):
Employed 165 (72.4) 56 (68.3) 55 (67.1) 54 (84.4)
—† Unemployed and seeking work 11 (4.8) 4 (4.9) 3 (3.7) 4 (6.3)
Unemployed and not seeking work 52 (22.8) 22 (26.8) 24 (29.3) 6 (9.4)
No of children (n=232):
≥1 169 (72.8) 61 (74.4) 64 (76.2) 44 (66.7) 0.40
None 63 (27.2) 21 (25.6) 20 (23.8) 22 (33.3)
Community or setting (n=233)‡:
Urban 192 (82.8) 65 (78.3) 73 (86.9) 54 (81.8)
0.34
Rural 41 (17.7) 18 (21.7) 11 (13.1) 12 (18.2)
Time since genetic testing (years)
(n=150):
≤4 77 (51.3) 37 (50.0) 40 (52.6) N/A
0.80 5-9 35 (23.3) 19 (25.7) 16 (21.1) N/A
≥10 38 (25.3) 18 (24.3) 20 (26.3) N/A
Experience with people with
Huntington’sd i s e a s e( n =226):
No prior experience 44 (19.5) 15 (18.5) 16 (19.8) 13 (16.0)
0.057
Known people with early symptoms 25 (11.1) 15 (18.5) 3 (3.7) 7 (8.6)
Known people with severe disease or
who have died
157 (69.5) 51 (63.0) 62 (76.5) 44 (54.3)
Time since learning of family history of
Huntington’s disease (years) (n=211):
≤9 61 (28.9) 23 (29.9) 18 (24.3) 20 (33.3)
0.38
10-19 56 (26.5) 25 (32.5) 15 (20.3) 16 (26.7)
20-29 48 (22.7) 15 (19.5) 19 (25.7) 14 (23.3)
30-39 33 (15.6) 11 (14.3) 14 (18.9) 8 (13.3)
≥40 13 (6.2) 3 (3.9) 8 (10.8) 2 (3.3)
*Missing values are excluded, values are two-sided. Analysis by 2×3 Pearson’s χ
2 test for categorical variables, and one-way analysis of variance for
continuous variables.
†Does not meet assumptions of χ
2 test.
‡Based on Statistics Canada’s rural postal code definition (Statistics Canada. Rural and small town Canada analysis bulletin. 2001 November 3(3)).
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level of distress they experienced, in general, on a scale
of 1-5, with 5 being the most distressing.
Demographic information
Respondents were asked to report their age, sex, mar-
ital status, employment status, whether they had chil-
dren, highest level of education attained, cultural
background, income level, type(s) of insurance pur-
chased, and which parent had Huntington’s disease
and the age of disease onset.
Administration of the survey
The questionnaires were administered during indivi-
duals’ annual scheduled clinic appointments or by
mailbetweenJuneandDecember2006.UsingtheDill-
mantailoreddesignsurveymethod,
27wemailedpostal
respondentsthequestionnaire,anintroductoryletter,a
postage-paid return envelope, and a $25 honorarium
by health professionals at each clinic. Written consent
was obtained from all respondents.
Statistical analysis
Descriptive statistics were calculated for the experi-
ences and prevalence of genetic discrimination. We
usedFisher’sexacttestand Pearson’sχ
2testsofsignifi-
cance to investigate baseline demographic differences
between the study groups (tested positive, tested nega-
tive, and not tested) and differences between the
groupsreportingexperiencesofgeneticdiscrimination
in the six settings. Significance tests were two tailed,
and α was set at 0.05. The false discovery rate
procedure
28 was used for multiple comparisons in our
exploratory analyses (differences in genetic discrimi-
nation between groups within the various settings,
representing 30 comparisons). Since fewer compari-
sons were being made in our hypothesis-driven ana-
lyses (differences in genetic discrimination between
all tested, tested positive, tested negative, and untested
respondents—thatis,fourcomparisons),correctionfor
multiple comparisons was unnecessary.
RESULTS
Characteristics of the respondents
Of 299 people invited to participate, 239 returned a
completed questionnaire, representing a response
rate of 80%. Six surveys were excluded because the
individuals had UHDRS disease scores >2 at some
pointafterconsentingtojointhestudybutbeforecom-
pleting the survey questionnaire, rendering an
adjusted response rate of 79.5% (233/293). Table 1
shows the characteristics of the remaining 233 asymp-
tomatic respondents. No significant differences in
baseline characteristics were detected between the
study groups. The sociodemographic characteristics
of our sample are similar to those of other Hunting-
ton’sdiseasepopulationswhoattendHuntington’sdis-
ease clinics
29-32 except that our sample was somewhat
older and better educated. Additionally, responders
and non-responders did not significantly differ with
respect to sex (P=0.206), average age (P=0.077),
genetic test status (P=0.334), and mutation status
(P=0.365) (details in supplemental table A on
bmj.com).
Nature and extent of genetic discrimination
Genetic discrimination was reported by 93 respon-
dents (39.9%). Discrimination experiences were most
prevalent in insurance (29.2%), family (15.5%), and
social (12.4%) settings, with discrimination in employ-
ment, healthcare, and public sector settings reported
much less often (table 2).
There were no significant differences in reported
experiencesofgeneticdiscriminationintheinsurance,
healthcare, and public sector settings among respon-
dents who had been genetically tested compared with
those not, nor by those who tested positive compared
with those who tested negative (table 3). Althoughnot
atlevelsconsideredsignificantafteradjustingformulti-
ple comparisons, respondents who had been
Table 2 |Settings of genetic discrimination experiences
reported by 233 asymptomatic people at risk for
Huntington’sd i s e a s e
Setting
No(%)ofrespondentswho
experienced
discrimination
Overall 93 (39.9)
Insurance:
By life insurance company or agent 63 (27.0)
Bylongtermdisabilitycompanyoragent 49 (21.0)
By mortgage company or agent 13 (5.6)
Family:
When making choices about having
children
27 (11.6)
By family member 15 (6.4)
By spouse 13 (5.6)
Social:
By friend 18 (7.7)
When establishing a relationship 14 (6.0)
By boyfriend or girlfriend 9 (3.9)
By community 7 (3.0)
At school 5 (2.1)
By religious organisation 2 (0.9)
Employment:
At work 15 (6.4)
When getting a job 7 (3.0)
Health care:
When getting medical care 11 (4.7)
By doctor 8 (3.4)
By other healthcare professional 7 (3.0)
By genetic counselling service 5 (2.1)
Public sector:
When getting access to or custody of
children
5 (2.1)
In the law courts 4 (1.7)
By adoption agency 3 (1.3)
By blood bank 2 (0.9)
By armed forces 2 (0.9)
Respondents selected all that applied.
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larlythosewhotestedpositive,tendedtoreporthigher
levels of genetic discrimination in interpersonal
domains such as family, social, and employment set-
tings rather than institutional related settings.
Genetic testing and genetic discrimination
Overall, tested and untested respondents reported
similar levels of discrimination (71 (42.5%) v 22
(33.3%), Fisher’s exact test P=0.236). However, when
comparing discrimination experiences between those
who tested positive for the mutation, those who tested
negative, and those who remained untested, the tested
positive respondents reported the highest levels of dis-
crimination (42 (50.6%) tested positive v 29 (34.5%)
tested negative v 22 (33.3%) untested, χ
2 test P=0.046;
and testedpositive v testednegative, Fisher’sexact test
P=0.042). Interestingly, the tested negative and
untested respondents reported similar levels of discri-
mination experiences (29 (34.5%) v 22 (33.3%), Fish-
er’s exact test P=1.00).
Reported reasons for genetic discrimination
Respondents’ family history was reported as the main
reason for genetic discrimination. Among the 71 tested
respondents who reported genetic discrimination, 41
attributed their experiences to their family history,
whereas only 13 believed that their genetic test results
were the main reason for their discriminatory experi-
ences. Seventeen tested respondents attributed their
experiencestobothfamilyhistoryandgenetictestresults.
Psychological distress and genetic discrimination
Psychologicaldistresswassignificantlyassociatedwith
the experience of genetic discrimination—P≤0.0001
for discrimination based on family history, and
P=0.011fordiscriminationbasedongenetictestresults
(because of the small sample sizes, ranks 1-3 and 4-5
were collapsed to represent low-moderate and high
levels of distress respectively). Further, experiencing
genetic discrimination in more situations was asso-
ciated with increased levels of distress (Pearson’s pro-
duct-moment correlation coefficient r=0.384 based on
family history and 0.526 based on genetic test results,
both P<0.001).
DISCUSSION
This is the first study to report on the nature and pre-
valence of genetic discrimination among an asympto-
matictestedanduntestedpopulationandtodistinguish
between discrimination based on family history and
genetic test results. Despite previous claims that
genetic discrimination is rare,
3334 discrimination was
reportedbynearly40%oftheindividualswe sampled.
Genetic discrimination occurred most often in refer-
encetolifeanddisabilityinsurance,andamongfamily
and friends (12.4-29.2%). Surprisingly, there were few
reports of genetic discrimination in employment,
healthcare, or public sector settings (3.9-6.9%). Inter-
estingly, family history seems to be a major reason for
experiences of genetic discrimination. Psychological
distress was strongly associated with genetic discrimi-
nation (P<0.001).
Nearly one in three of the respondents reported
insurance discrimination, largely by life and disability
insurance companies in the forms of insurance rejec-
tion, premium increases, or requests to take a predic-
tive test. Surprisingly, however, these experiences
were not influenced by individuals’ participation in
genetic testing or their genetic test results; rather they
were attributed to family history. Before the introduc-
tion ofthe Huntington’sdiseasepredictivetesting pro-
gramme, concerns were raised that insurance
companiesmightmisusegenetictestingbydemanding
“such a test before entering into a contract with some-
oneatrisk.”
1516Althoughsuchrequestsoccurred,they
were not limited to the tested group. Our results there-
fore do not support apprehensions that genetic testing
Table 3 |Prevalence of genetic discrimination experiences reported by 233 asymptomatic people at risk for Huntington’s
disease by genetic testing and test result. Values are numbers (percentages) unless stated otherwise
Setting of
discrimination
Total
(n=233)
Genetically tested
Not tested
(n=66)
P value of difference
Total
(n=167)
Positive test
(n=83)
Negative
test (n=84)
Total tested v
not tested*
Positive test v
negative test* Overall†
Overall 93 (39.9) 71 (42.5) 42 (50.6) 29 (34.5) 22 (33.3) 0.236 0.042 0.046
Insurance 68 (29.2) 53 (31.7) 31 (37.3) 22 (26.2) 15 (22.7) 0.202 N/A 0.112
Family 36 (15.5) 31 (18.6) 19 (22.9) 12 (14.3) 5 (7.6) 0.044‡ 0.168 0.034§
Social 29 (12.4) 25 (15.0) 17 (20.5) 8 (9.5) 4 (6.1) 0.078 0.053 0.018¶
Employment 16 (6.9) 15 (9.0) 12 (14.5) 3 (3.6) 1 (1.5) —** 0.003†† 0.003††
Health care 20 (8.6) 14 (8.4) 11 (13.3) 3 (3.6) 6 (9.1) 0.802 N/A 0.081
Public sector 9 (3.9) 9 (5.4) 5 (6.0) 4 (4.8) 0 (0.0) —** —** —**
*Fisher’s exact test. Values are two sided.
†Positive test v negative test v not tested. Pearson’s χ
2 test. Values are two sided.
N/A: post hoc comparison is not applicable as primary comparison was not significant (see corresponding overall P value).
‡P value did not reach the required significance level adjusted for false discovery rate (P≤0.014).
§Post hoc P value (positive test v not tested, P=0.013) was above the required significance level adjusted for false discovery rate (P≤0.007).
¶Post hoc P value (positive test v not tested, P=0.016) was above the required significance level adjusted for false discovery rate (P≤0.011).
**Assumptions of the χ
2 test not met.
††Post hoc P values (positive test v not tested, P=0.007; negative test v not tested, P=0.016) were above the required significance levels adjusted for
false discovery rate (P≤0.005 and P≤0.010, respectively).
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related to insurance.
Surprisingly, family and social circles were the next
major source of discriminatory experiences. One in
five respondents reported genetic discrimination in
thesesettings,mostlyinreferencetoreproductivedeci-
sion making and relationships. No survey to date has
explored discrimination in areas other than institu-
tional domains. Discrimination in the family must be
viewedthroughawiderlensthatcapturestheprofound
impact the presence of Huntington’s disease and pre-
dictive testing can have on the family system. Often
when Huntington’s disease is present in a family, it
becomespartofafamily’sidentityandpatternofbeha-
viour.
The advent of predictive testing for Huntington’s
disease introduced the opportunity to remove the
uncertainty of a looming disease and to plan for the
future, but with it comes the potential inability to
cope with the predictive test results, both by the indi-
vidual as well as by family members. This is particu-
larly challenging giventhat no treatmentexists to slow
or prevent the disease. There was apprehension that
disclosure of test results may precipitate depression,
breakdownoffamilyrelationships,orsuicide.
1516Like-
wise, the availability of genetic testing creates new
pressures and dilemmas for the family.
35 The decision
to test itself can become a “litmus test by which rela-
tives judge each other’s loyalty to the family,”
35 and
testing often produces disruption within the family.
36
Clearly, the availability of predictive testing produces
reactionstowardsthosewhotestandthosewhochoose
not to test. This study provides further insight into the
impact ofgenetic testing onthe familyand highlightsa
need to pay special attention to family and social
domains during pretest and post-test counselling.
Theseresultsalsosuggestthe needforfurtherresearch
on genetic discrimination in this area.
Interestingly, tested respondents attributed their
experiences of genetic discrimination to their family
history more often than to their genetic test results.
These results lend further support to the similar levels
ofdiscriminationseenbetweenthetestedanduntested
groups. Indeed, regardless of testing status, most indi-
viduals believed that family history was the predomi-
nant reason for their discriminatory experiences.
Clearly, there is a need to shift the current focus of
genetic discrimination as a genetic testing issue to one
thatequallyhighlightstherolethatfamilyhistoryplays
in people’s lives.
Psychological distress was strongly associated with
genetic discrimination. Our results are consistent with
previously documented associations of distress with
racial, sexual, and ethnic discrimination.
26 Still, the
health outcomes of genetic discrimination have not
been described, raising the effects of genetic discrimi-
nation to a mental health issue which requires appro-
priate counselling and support.
Discrimination in employment, healthcare, and
public sector settings was infrequently cited by our
respondents. Despite concern for genetic
discrimination in employment,
17 little discrimination
seems to be occurring in this setting. The low levels
of discrimination in the healthcare domain support
the assumption that healthcare professionals have a
better understanding of genetic risk and are likely to
use such information appropriately. These findings
may also be influenced by the existence in Canada of
a healthcare system where access and treatment are
universal and not determined by employment.
Ourfindingsareparticularlyimportantinlightofthe
recent US federal Genetic Information Nondiscrimi-
nation Act. This prohibits group and individual health
insurers from using a person’s and his or her family’s
genetic information in determining eligibility and set-
ting premiums for health insurance and from request-
ingorrequiringpotentialapplicantstoprovidegenetic
test results. Furthermore, it bars employers from using
genetictestresultsintheirhiring,firing,jobplacement,
or promotion decisions.
8 Such legislative protection
against genetic discrimination in health insurance
would make a basic level of coverage accessible to all
members of society without the need to disclose
geneticinformation.However,byfocusingexclusively
on health insurance and employment, the legislation
does not address the commonly occurring discrimina-
tionwithregardtolifeanddisabilityinsurance,northe
genetic discrimination that occurs within social and
family relationships. The areas of greatest need may
not be protected by this legislation.
Legislation is not a feasible approach to regulate
interactions within family and social relationships.
Insightintothepsychodynamicsofgeneticdiscrimina-
tion would be important in the development of appro-
priate intervention strategies to mitigate
discrimination. Strategies might include comprehen-
sive education and support programmes to inform
and engage society about genetics to reduce ignorance
and the resultant level of stigma and discrimination.
Support groups are common for many hereditary dis-
orders and could be used to strengthen social support
networks and assist those who wish to lodge formal
complaints against genetic discrimination. Ultimately,
such structural interventions may be necessary to
change the social climate around genetic disease.
Limitations of study
Our findings should be interpreted in light of our
study’s methodological limitations. Our findings are
based on data from Canada, and may not be generali-
sabletojurisdictionswithoutuniversalhealthcare.The
crosssectional designdidnot allowus to makeconclu-
sions about causal effects of genetic status or family
history on experiences of genetic discrimination.
Longitudinal studies with larger sample sizes are
needed to draw definite causal conclusions and con-
firm the presence or absence of associations. In addi-
tion, discrimination experiences were self reported
and couldnot bevalidated; thus,reportedexperiences
are the respondents’ perception of discrimination. It is
thus possible that our results represent an overly opti-
mistic view of the nature and extent of genetic
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be more aware of the issue of genetic discrimination
and thus be better able to recognise it (or its occur-
rence).
Our sampling strategy relied on reports of discrimi-
nation among people attending clinics and participat-
ing in research who may be more resourceful and
betterabletocopewiththepsychosocialconsequences
of testing or research. The motivation and emotional
wellbeingofpeoplewhoareconnectedwithclinicsand
participate in research or predictive testing may there-
fore be unrepresentative of the general population at
risk of Huntington’s disease. Finally, our measure of
psychologicaldistresswasnota diagnosticinstrument.
Psychological distress is a multidimensional concept
that may not be fully captured by a single item.
Implications of our results
Our findings have implications beyond Huntington’s
disease. Indeed, the predictive testing programme for
Huntington’s disease,a classic monogenicdisease,has
served as a model for presymptomatic testing for sev-
eralgenetic and non-genetic diseases.
37-39 Our findings
also provide insights for genetic screening pro-
grammes for diseases associated with genes of small
effect as well as other late onset and neurological con-
ditions. Predictive testing for Huntington’s disease
represents an extreme model for an autosomal domi-
nantdiseaseofhighpenetranceforwhichthereisawell
validatedtest.Even in such an extremecase, ourstudy
highlights the importance of family history in people’s
experiences of genetic discrimination. Ultimately,
asymptomatic individuals at genetic risk are at similar
riskfordiscriminationbecauseoftheirlabelofhavinga
family history of disease.
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